Patient description: A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Hepatocellular Carcinoma Male or female patients from 18 to 75 years of age with a diagnosis of HCC. A diagnosis of HCC based on the diagnostic for HCC used by the European Association for the Study of the Liver (EASL). The patient has not been previously treated with surgery, radiation therapy, radiofrequency ablation, percutaneous ethanol or acetic acid injection, or cryoablation, or any other treatment with chemotherapeutic agents or sorafenib. The patient has not been previously treated with any anti-viral agents, including interferon or nucleosides analogs (NAs). Adults patients with a diagnosis of HCC which is not amenable to surgical resection ,local ablative therapy or any other radically cured treatment. The MDT group of HCC agree to administer TACE in this patient. Patients must have at least one tumor lesion that can be accurately measured according to EASL criteria. No serious concurrent medical illness. Unresectable TNM stage Ⅲ or Ⅳ disease. Zubrod-ECOG-WHO performance status: 0 or 1. and the estimated survival more than 4 months. Not pregnant or breast-feeding patients No significant renal impairment (creatinine clearance < 30 mL/minute) or patients on dialysis No current infections requiring antibiotic therapy Not on anticoagulation or suffering from a known bleeding disorder No unstable coronary artery disease or recent MI Ability to understand the protocol and to agree to and sign a written informed consent document The following laboratory parameters at baseline: Platelet count ≥ 70,000/µL Hemoglobin ≥ 8.5 g/dL Absolute neutrophil count (ANC) >1,500/mm3 Total bilirubin ≤ 1.5 mg/dL Serum albumin ≥ 35 g/L Serum creatinine ≤ 1.5 x upper limit of normal PT prolong time less than 3 seconds Cirrhotic status of Child-Pugh class A only ALT<2×upper limit of normal Hepatitis B surface antigen positive If hepatitis B e antigen positive, HBV DNA level <2000IU/mL; If hepatitis B e antigen negative, HBV-DNA<200IU/mL  History of HIV or HCV infection. History of organ allograft Known or suspected allergy to the investigational agents or any agent given in association with this trial. Evidence of bleeding diathesis. Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry. Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of study entry. Serious non-healing wound, ulcer, or bone fracture Known central nervous system tumors including metastatic brain disease Any event > grade 2 National Cancer Institute [NCI]-Common Terminology for Adverse Events [CTCAE] version 3.0 Severe complication after TACE. History of hepatotoxic medication within 8 wk prior to the current treatment. History of corticosteroid administration